Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instab
- PDF / 902,259 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 96 Downloads / 201 Views
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open‑label prospective pivotal trial Jingde Chen1 · Ming Quan1 · Zhiqin Chen1 · Tianmei Zeng2 · Yandong Li1 · Ying Zhou1 · Yanan Hai1 · Yong Gao1 Received: 8 January 2020 / Accepted: 7 May 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers are prone to response to programmed cell death-1 (PD-1) checkpoint inhibitors. Therefore, we explored the efficacy and safety of a PD-1 checkpoint inhibitor camrelizumab in advanced or metastatic solid tumour with dMMR/MSI-H. Methods Patients with dMMR/MSI-H advanced or metastatic solid tumours who had received at least one line of prior systemic chemotherapy were recruited. Camrelizumab was given intravenously 200 mg every 2-week treatment cycle. The primary endpoint was objective response rate according to Response Evaluation Criteria in Solid Tumours v1.1. Results Twelve patients were enrolled. As data cutoff, eight patients (66.7%, 95% CI 34.9–90.1) achieved objective response. Disease control rate reached 100% (95% CI 73.5–100). Progression-free survival rate at 12 months was 83.3% (95% CI 48.2–95.6), and overall survival rate at 12 months was 90% (95% CI 47.3–98.5). The most common treatment-related adverse events were reactive cutaneous capillary endothelial proliferation (100%), increased alanine aminotransferase (41.7%), and increased aspartate aminotransferase (41.7%). Conclusions Camrelizumab provided durable objective response and disease control in pre-treated patients with dMMR/ MSI-H advanced or metastatic solid tumour, being a promising treatment option for these patients. Keywords dMMR/MSI-H · Camrelizumab · Solid tumour · SHR-1210
Background Currently, immunotherapy that inhibits checkpoint interaction between programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) has been proven to be a promising treatment strategy in many malignancies that have
Jingde Chen and Ming Quan contributed equally to this work. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00432-020-03251-5) contains supplementary material, which is available to authorized users. * Yong Gao [email protected] 1
Shanghai East Hospital, Tongji University School of Medicine, No. 150 Ji‑Mo Rd., Shanghai 200120, China
Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Second Military Medical University, Shanghai, China
2
limited therapeutic options (Fritz and Lenardo 2019). However, there are still a lot of patients who could not benefit from antibodies that block the PD-1 and PD-L1 interaction. In this context, discovery of potential biomarkers to select immunotherapy responders would minimize unnecessary exposure of non-responders. Microsatellites, also defined as “short-tandem repeats”, are repe
Data Loading...
